Evaxion Biotech A/S has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform. Evaxion has developed three personalized cancer vaccine candidates with the use of its AI-Immunology platform. Two of these – EVX-01 and EVX-02 – have completed clinical phase 1 testing and EVX-01 is currently in phase 2, while the third – EVX-03 – is an IND-ready vaccine candidate. The AI-Immunology platform identifies cancer vaccine targets, so called neoantigens, and assigns a prediction score reflecting the likelihood of each vaccine target to elicit a specific immune response against the tumor. In all three clinical trials, a statistically significant correlation was observed between the AI-Immunology prediction scores and the immunological responses measured in the patients, with the most robust responses being generated by vaccine targets with the highest AI-Immunology prediction scores.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech announces clinical data for AI-Immunology platform
- Evaxion’s AI Platform Boosts Vaccine Target Prediction
- Evaxion Biotech Charts Future with Innovative Immune Therapies
- Evaxion Biotech Partners with Merck for Vaccine Development
- Evaxion Biotech deal underscores potential of AI models, says H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com